Stockscreener 앱 받기
58.47
4.37%
2.45
시간 외 거래:
58.47
전일 마감가:
$56.02
열려 있는:
$56
하루 거래량:
330.83K
Relative Volume:
0.54
시가총액:
$1.73B
수익:
$232.39M
순이익/손실:
$-26.79M
주가수익비율:
-54.12
EPS:
-1.0804
순현금흐름:
$4.41M
1주 성능:
+3.29%
1개월 성능:
-6.46%
6개월 성능:
+10.15%
1년 성능:
+192.79%
1일 변동 폭
$55.30
$58.54
1주일 범위
$55.30
$59.00
52주 변동 폭
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
58.47 | 1.69B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio earnings ahead: First results as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Pass Above Fifty Day Moving AverageHere's What Happened - marketbeat.com
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A - Stock Titan
AnaptysBio Announces Results of 2026 Annual Stockholders Meeting Voting - Kalkine Media
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings? - Sahm
Price-Driven Insight from (ANAB) for Rule-Based Strategy - Stock Traders Daily
AnaptysBio (ANAB) Rallies 3.36% as Biotech Momentum Builds Toward Key ResistanceGolden Cross - dars.gov.et
AnaptysBio (ANAB) awards CEO 53,334 performance stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO - Stock Titan
AnaptysBio Inc (ANAB) Stock News Today - TradingKey
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada
AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a 59% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
ANAB Q2'26 Earnings: revenue estimate is 17.33M USD - TradingView
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute - The Globe and Mail
AnaptysBio and Tesaro set post-trial briefing schedule after July 2026 trial - TradingView
AnaptysBio: The Royalty Waterfall Is About To Reverse - Seeking Alpha
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AnaptysBio, Inc. Revenue Breakdown – NASDAQ:ANAB - TradingView
ANAB|AnaptysBio Inc|Price:56.610|Chg%:+1.840 - TradingKey
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Cash Flow - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANAB|AnaptysBio Inc|Price:53.486|Chg%:-0.124 - TradingKey
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760 - TradingKey
TradingKey - TradingKey
AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC - MarketBeat
ANAB|AnaptysBio Inc|Price:56.102|Chg%:+0.632 - TradingKey
AnaptysBio Inc (ANAB) Income Statement - TradingKey
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Affinity Asset Advisors LLC Boosts Position in AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6%Here's What Happened - MarketBeat
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio Declines 2.14% as Shares Test Key Support ZoneVolatility Term Structure - dars.gov.et
AnaptysBio Q1 2026 Earnings: Significant EPS Miss as Pipeline Costs Weigh on ResultsEarnings Call Q&A - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio (ANAB) Surges 6.9%: Potential Breakout or Resistance Test?Box Spread - dars.gov.et
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%Here's Why - MarketBeat
High Growth Tech Stocks In The US Market - simplywall.st
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Trading 5.3% HigherShould You Buy? - MarketBeat
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial? - Sahm
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):